TAKEDA PHARMACEUTICAL CO LTD

Drug pipeline (149)

Asset	Stage	Revenue	Trials	Status
ACTOPLUS MET	approved	—	14	approved
ACTOPLUS MET XR	approved	—	14	approved
ACTOS	approved	—	0	—
ADDERALL XR 10	approved	—	3	approved
ADDERALL XR 15	approved	—	3	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (1326)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT03808493	phase1	completed	2019-01-30	2019-03-12	Takeda	A Bioequivalence (BE) Study of TAK-438 Orally Disintegrating (OD) Tablet
NCT02401464	phase1	completed	2015-03-01	2015-05-01	Takeda	A Bioequivalence Study of TAK-536 Pediatric Formulation
NCT03437564	phase1	completed	2018-02-16	2018-04-13	Takeda	A Bioequivalence Study of the Lu AA21004 20 mg and 2×10 mg Tablets
NCT00500149	phase3	completed	2007-06-13	2007-12-05	Shire	A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT03878953	phase3	withdrawn	2022-08-31	2023-05-31	Shire	A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism

FDA applications (72)

Application

Approved

Type

Applicant

Products

NDA 220605

2026-08-28

NDA

TAKEDA PHARMS AM

NDA 213976

2024-02-09

NDA

TAKEDA PHARMACEUTICALS USA INC

BLA 125795

2023-11-09

BLA

TAKEDA PHARMACEUTICALS U.S.A., INC.

NDA 217564

2023-11-08

NDA

TAKEDA PHARMACEUTICALS USA INC

BLA 761133

2023-09-27

BLA

TAKEDA PHARMACEUTICALS U.S.A., INC.